IP Library › Granted Patent US 12,351,572
Granted Patent B2
US 12,351,572 · App. 18/335,262 · Granted Jul 8, 2025

Substituted 1,2,4-triazoles as TYK2 inhibitors

Inventors: Bohan Jin (San Francisco, CA); Qing Dong (San Francisco, CA); Gene Hung (San Francisco, CA); Stephen W. Kaldor (San Francisco, CA)
Assignee: Alumis Inc.
C07D401/14C07D401/12C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,572
App. No.
18/335,262
Granted
Jul 8, 2025
Kind
B2
Abstract

Described herein are compounds, for example, substituted 1,2,4-triazoles, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Claims (12)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising: a pharmaceutically acceptable excipient, and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. A compound:

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising: a pharmaceutically acceptable excipient and the compound of claim 3 or a pharmaceutically acceptable salt thereof.

5. A compound:

or a pharmaceutically acceptable salt thereof.

6. A compound:

or a pharmaceutically acceptable salt thereof.

7. A compound:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2023
From: JIN, BOHAN; DONG, QING; HUNG, GENE; KALDOR, STEPHEN W.
To: ESKER THERAPEUTICS, INC.
Reel/Frame 064392/0947 →
CHANGE OF NAME Recorded Jul 26, 2023
From: ESKER THERAPEUTICS, INC.
To: ALUMIS INC.
Reel/Frame 064396/0506 →
Continuity (13)
Continuation 17713646 · Apr 5, 2022
Continuation 17891817 · Aug 19, 2022
Continuation 17713646 · Apr 5, 2022
Continuation 17243508 · Apr 28, 2021
Continuation 16938183 · Jul 24, 2020
Continuation PCTUS2019057485 · Oct 22, 2019
Provisional Application 62907354 · Sep 27, 2019
Provisional Application 62893721 · Aug 29, 2019
Provisional Application 62875449 · Jul 17, 2019
Provisional Application 62839459 · Apr 26, 2019
Provisional Application 62756942 · Nov 7, 2018
Provisional Application 62749003 · Oct 22, 2018
Related Publication 20230391751A1 · Dec 7, 2023
References Cited (143)
US 8933084B2 · Andrews et al. · 2015 [cited by applicant]
US 9096609B2 · Hoflack et al. · 2015 [cited by applicant]
US 9370520B2 · Hoflack et al. · 2016 [cited by applicant]
US 9493476B2 · Andrews et al. · 2016 [cited by applicant]
US 9714258B2 · Cui et al. · 2017 [cited by applicant]
US 9718822B2 · Andrews et al. · 2017 [cited by applicant]
US 9750744B2 · Andrews et al. · 2017 [cited by applicant]
US 9840519B2 · Andrews et al. · 2017 [cited by applicant]
US 9902741B2 · Andrews et al. · 2018 [cited by applicant]
US 10180422B1 · Sigal · 2019 [cited by applicant]
US 10246466B2 · Cui et al. · 2019 [cited by applicant]
US 10294242B2 · Cui et al. · 2019 [cited by applicant]
US 10316044B2 · Cui et al. · 2019 [cited by applicant]
US 10370727B2 · Nanda et al. · 2019 [cited by applicant]
US 10378068B2 · Nanda et al. · 2019 [cited by applicant]
US 10618912B2 · Cui et al. · 2020 [cited by applicant]
US 10647730B2 · Andrews et al. · 2020 [cited by applicant]
US 10655186B2 · Nanda et al. · 2020 [cited by applicant]
US 10688100B2 · Andrews et al. · 2020 [cited by applicant]
US 10689400B2 · Cui et al. · 2020 [cited by applicant]
US 10724102B2 · Nanda et al. · 2020 [cited by applicant]
US 10745416B2 · Rogers et al. · 2020 [cited by applicant]
US 10907215B2 · Nanda et al. · 2021 [cited by applicant]
US 11053219B2 · Jin et al. · 2021 [cited by applicant]
US 20110230467A1 · Shirakami et al. · 2011 [cited by applicant]
US 20150299214A1 · Uchida et al. · 2015 [cited by applicant]
US 20160024114A1 · Blom et al. · 2016 [cited by applicant]
US 20160207883A1 · Shirahase et al. · 2016 [cited by applicant]
US 20170338422A1 · Wang et al. · 2017 [cited by applicant]
US 20180325901A1 · Cui et al. · 2018 [cited by applicant]
US 20190247398A1 · Zhao et al. · 2019 [cited by applicant]
US 20190381048A1 · Cui et al. · 2019 [cited by applicant]
US 20200123166A1 · Bryan et al. · 2020 [cited by applicant]
US 20200157119A1 · Cui et al. · 2020 [cited by applicant]
US 20200190199A1 · Chuang et al. · 2020 [cited by applicant]
US 20200216451A1 · Zhao et al. · 2020 [cited by applicant]
US 20200291042A1 · Dai et al. · 2020 [cited by applicant]
US 20200330452A1 · Rickard et al. · 2020 [cited by applicant]
US 20200385386A1 · Wu et al. · 2020 [cited by applicant]
US 20200405725A1 · Wang et al. · 2020 [cited by applicant]
US 20210000830A1 · Kozaki et al. · 2021 [cited by applicant]
US 20210023086A1 · Bilenker et al. · 2021 [cited by applicant]
US 20210047330A1 · Wang et al. · 2021 [cited by applicant]
US 20220235035A1 · Jin et al. · 2022 [cited by applicant]
US 20230021554A1 · Jin et al. · 2023 [cited by applicant]
CN 104884454A · 2015 [cited by applicant]
CN 105111151A · 2015 [cited by applicant]
CN 107735399A · 2018 [cited by applicant]
CN 113874021A · 2021 [cited by applicant]
EP 2361902A1 · 2011 [cited by applicant]
EP 2428508A1 · 2012 [cited by applicant]
EP 3040329A1 · 2016 [cited by applicant]
EP 3607944A1 · 2020 [cited by applicant]
JP 2010503690A · 2010 [cited by applicant]
JP 2011518157A · 2011 [cited by applicant]
JP 2014501705A · 2014 [cited by applicant]
JP 2015503575A · 2015 [cited by applicant]
JP 2016506369A · 2016 [cited by applicant]
JP 2016539152A · 2016 [cited by applicant]
JP 2017512749A · 2017 [cited by applicant]
JP 2018522823A · 2018 [cited by applicant]
RU 2005106871A · 2005 [cited by applicant]
WO 200247690A1 · 2002 [cited by applicant]
WO 2006105222A2 · 2006 [cited by applicant]
WO 2008036277A1 · 2008 [cited by applicant]
WO 2009136995A2 · 2009 [cited by applicant]
WO 2010058846A1 · 2010 [cited by applicant]
WO 2010128659A1 · 2010 [cited by applicant]
WO 2012061418A2 · 2012 [cited by applicant]
WO 2012061428A2 · 2012 [cited by applicant]
WO 2012159557A1 · 2012 [cited by applicant]
WO 2013001310A1 · 2013 [cited by applicant]
WO 2013104573A1 · 2013 [cited by applicant]
WO 2014074661A1 · 2014 [cited by applicant]
WO 2015030189A1 · 2015 [cited by applicant]
WO 2015069310A1 · 2015 [cited by applicant]
WO 2015084998A1 · 2015 [cited by applicant]
WO 2015123453A1 · 2015 [cited by applicant]
WO 2016196776A2 · 2016 [cited by applicant]
WO 2017004342A1 · 2017 [cited by applicant]
WO 2017087590A1 · 2017 [cited by applicant]
WO 2017125534A1 · 2017 [cited by applicant]
WO 2018067432A1 · 2018 [cited by applicant]
WO 2018081417A2 · 2018 [cited by applicant]
WO 2018165240A1 · 2018 [cited by applicant]
WO 2018170381A1 · 2018 [cited by applicant]
WO 2018186366A1 · 2018 [cited by applicant]
WO 2019023417A1 · 2019 [cited by applicant]
WO 202019376A1 · 2020 [cited by applicant]
WO 2020086616A1 · 2020 [cited by applicant]
WO 2020154474A1 · 2020 [cited by applicant]
WO 2020156311A1 · 2020 [cited by applicant]
WO 2020163778A1 · 2020 [cited by applicant]
WO 2020185755A1 · 2020 [cited by applicant]
WO 2020198379A1 · 2020 [cited by applicant]
WO 2021092246A1 · 2021 [cited by applicant]
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. [cited by examiner]
Coffey, G., et al., “Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis”, The Journal of Pharmacology and Experimen tal Therapeut… [cited by applicant]
EP Examination Report for European Patent Application No. 19877015.8, mailed May 30, 2023. [cited by applicant]
Examination Report for Indian Patent Application No. 202117022424, mailed Nov. 29, 2022. [cited by applicant]
Extended EP Search Report for European Patent Application No. 19877015.8, mailed Sep. 21, 2022. [cited by applicant]
Extended EP Search Report for European Patent Application No. 20769748.3, mailed Dec. 22, 2022. [cited by applicant]
First Examination Report for Indian Patent Application No. 202117041694, mailed May 8, 2023. [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2021/050649, mailed Mar. 30, 2023. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/057485, mailed Feb. 7, 2020. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/021850, mailed Jun. 24, 2020. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/050649, mailed Dec. 6, 2021. [cited by applicant]
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205-213. [cited by applicant]
Jordan, V. C., “Tamoxifen: a most unlikely pioneering medicine”, Nature Reviews: Drug Discovery, 2:205-213, (2003). [cited by applicant]
Office Action for Brazil Patent Application No. BR112021007679-4, mailed May 9, 2023. [cited by applicant]
Office Action for Chile Patent Application No. 202100989, mailed Oct. 17, 2022. [cited by applicant]
Office Action for Russian Patent Application No. 2021114368, mailed Feb. 28, 2022. [cited by applicant]
Office Action for Saudi Patent Application No. 521421806, mailed Aug. 31, 2022. [cited by applicant]
Office Action for Singapore Patent Application No. 11202104017V, mailed Sep. 1, 2022. [cited by applicant]
Office Action for Vietnam Patent Application No. 1-2021-02921, mailed Jul. 26, 2023. [cited by applicant]
Partial European Search Report for EP Patent Application No. 19877015.8, mailed Jun. 6, 2022. [cited by applicant]
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18. [cited by applicant]
Vippagunta, S. R., et al., “Crystalline solids”, Advanced Drug Delivery Reviews, 48(1):3-26, (2001). [cited by applicant]
Wrobleski, et al., “Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165”, J Med Chem 62(20):8973-8995 (2019). [cited by applicant]
Xu, S., et al., “Design, synthesis and biological evaluation of new molecules inhibi ting epidermal growth factor recep for threonine 790—+methionine 790 mutant”, Med. Chem. Commun., 3:1155-1159, (2012). [cited by applicant]
U.S. Appl. No. 16/938,183, filed Jul. 24, 2020, Bohan Jin et al. [cited by applicant]
U.S. Appl. No. 17/243,508, filed Apr. 28, 2021, Bohan Jin et al. [cited by applicant]
U.S. Appl. No. 17/713,646, filed Apr. 5, 2022, Bohan Jin et al. [cited by applicant]
U.S. Appl. No. 17/891,817, filed Aug. 19, 2022, Bohan Jin et al. [cited by applicant]
Extended European Search Report for EP Patent Application No. 20769748.3, mailed Dec. 22, 2022. [cited by applicant]
Examination Report for Indian Patent Application No. 202117041694, mailed May 8, 2023. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-523157, mailed Nov. 15, 2023. [cited by applicant]
Office Action for Chinese Patent Application No. 201980084885.9, mailed Dec. 27, 2023. [cited by applicant]
ACS. Registry Database, RN No. 42321-62-0 etc., Jun. 17, 2013. [cited by applicant]
Office Action for Chinese Patent Application No. 202080034800.9, mailed Nov. 29, 2023. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-552136, mailed Feb. 16, 2024. [cited by applicant]
Zhe Nie, et al., “Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities”, Bioorganic & Medicinal C… [cited by applicant]
Office Action for Singapore Patent Application No. 11202104017V, mailed Jan. 10, 2024. [cited by applicant]
Partial Supplementary European Search Report for European Patent Application No. 19877015.8, mailed Jun. 14, 2022. [cited by applicant]
Office Action for Mexican Patent Application No. MX/a/2021/004538, mailed Mar. 1, 2024. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-552136, mailed Feb. 20, 2024. [cited by applicant]
Office Action for Israel Patent Application No. 286248, mailed Mar. 27, 2024. [cited by applicant]
Office Action for Israel Patent Application No. 282487, mailed Apr. 9, 2024. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-523157, mailed Aug. 2, 2024. [cited by applicant]
Office Action for Chinese Patent Application No. 201980084885.9, mailed Aug. 10, 2024. [cited by applicant]
Extended European Search Report for European Patent Application No. 24203208.4, mailed Nov. 13, 2024. [cited by applicant]
Extended European Search Report for European Patent Application No. 24203217.5, mailed Jan. 20, 2025. [cited by applicant]
Ye Faqing, et al., “Medicinal Chemistry”, Zhejiang University Press, pp. 66-70, Jun. 30, 2012. [cited by applicant]